Mercados españoles cerrados

Equillium, Inc. (EQ)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
0,66400,0000 (0,00%)
Al cierre: 04:00PM EDT
0,6621 -0,00 (-0,29%)
Después del cierre: 05:03PM EDT

Equillium, Inc.

2223 Avenida De La Playa
Suite 105
La Jolla, CA 92037
United States
858 240 1200
https://www.equilliumbio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 44

Descripción

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Gobierno corporativo

El ISS Governance QualityScore de Equillium, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.